Fig. 2From: A prognostic nomogram for stage II/III rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgical resectionNomogram for predicting the OS at 24, 36 and 60 months. According to Nomogram’s estimate the cumulative risk of OS in patients no.30 at 24, 36 and 60 months is 0.0389, 0.07 and 0.131, respectively. *P < 0.05; **P < 0.01; ***P < 0.001. OS overall survival, CEA carcinoembryonic antigen, LODDS log odds of positive lymph nodesBack to article page